Taysha Gene Therapies News and Activities
Presence
Taysha Gene Therapies develops gene therapy medicines for severe nervous system diseases. Its services focus on research, clinical development, and treatment programs for patients, healthcare providers, and research partners.
Taysha Gene Therapies products and services overview:
- Gene therapies
- Clinical development
- Research services
- Drug pipeline
- Rare disease treatments
Revenue: ~$0 million
Employees: 80
Headquarters: Dallas, United States (USA)
Taysha Gene Therapies is one of the...
Taysha Gene Therapies is a company listed under the stock ticker TSHA (US).
Executives
View the org chart displaying its 14 main executives
Most searched biographies at Taysha Gene Therapies
- Sean Nolan, Chairman of the Board and Chief Executive Officer
- Laura Sepp-Lorenzino, Director
- Alison Long, Director
Create your alert
to follow the executive moves at Taysha Gene Therapies.
Biotechnology
Taysha Gene Therapies has 2,405 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).
Popular M&A news in Biotechnology
- Ona Therapeutics has just announced a $87 Million fundraising (posted on June 5 2026).
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
Popular contacts in Biotechnology
News
Press releases by Taysha Gene Therapies
- Taysha Gene Therapies to Participate in Upcoming August Investor Conferences | Taysha Gene Therapies
- Taysha Gene Therapies to Participate in Upcoming William Blair Biotech Focus Conference 2022 | Taysha Gene Therapies
- Taysha Gene Therapies Announces Annual Stockholder Meeting | Taysha Gene Therapies
- Taysha Gene Therapies to Participate in Upcoming June Investor Conferences and Convention | Taysha Gene Therapies
- Press Releases | Taysha Gene Therapies
- Press Releases | Taysha Gene Therapies
- Taysha Gene Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update | Taysha Gene Therapies
- Taysha Gene Therapies to Release First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 16 | Taysha Gene Therapies
- Taysha Gene Therapies Announces Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy | Taysha Gene Therapies
- Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-120 for the Treatment of Giant Axon Neuropathy (GAN) | Taysha Gene Therapies
- View more press releases Close
Social media about Taysha Gene Therapies
- Taysha Gene Therapies on Wikipedia, Google News & Yahoo Finance
- Taysha Gene Therapies on LinkedIn, X (Twitter) & YouTube
